リンパ増殖性障害治療薬の世界市場インサイト、2029年までの予測Global Lymphoproliferative Disorder Treatment Market Insights, Forecast to 2029 リンパ増殖性疾患(LPD)とは、リンパ球の異常な産生を特徴とする疾患群である。リンパ球はT細胞とB細胞に分類され、異常な再生を繰り返し、免疫増殖性障害を引き起こす。LPDはさらに、体内で見られる同一のB細胞... もっと見る
![]()
※当ページの内容はウェブ更新時の情報です。
サマリーリンパ増殖性疾患(LPD)とは、リンパ球の異常な産生を特徴とする疾患群である。リンパ球はT細胞とB細胞に分類され、異常な再生を繰り返し、免疫増殖性障害を引き起こす。LPDはさらに、体内で見られる同一のB細胞の数が多くなることもある。T細胞リンパ増殖性障害は、同種造血幹細胞移植(HSCT)によって治癒することができます。また、ステロイド、シクロスポリン、エトポシドの使用によって管理することもできます。A、およびエトポシドを使用します。市場分析・洞察:リンパ増殖性障害治療薬の世界市場 リンパ増殖性疾患治療薬の世界市場は、2023年の100万米ドルから2029年には100万米ドルに達すると予測され、予測期間中の年間平均成長率(CAGR)は %と予測されています。 リンパ増殖性障害治療剤の米国・カナダ市場は、2023年の100万ドルから2029年には100万ドルに達すると予測され、2023年から2029年の予測期間中にCAGR %で増加する見込みです。 リンパ増殖性疾患治療剤の中国市場は、2023年の100万ドルから2029年には100万ドルに達すると推定され、2023年から2029年までの予測期間中にCAGR %で増加すると考えられています。 リンパ増殖性疾患治療薬のヨーロッパ市場は、2023年の100万ドルから2029年には100万ドルに達すると推定され、2023年から2029年までの予測期間中にCAGR %で増加するとされています。 リンパ増殖性障害治療薬の世界の主要企業は、Atara Biotherapeutics、Novartis、Janssen Global Services、MSD、Bristol-Myers Squibb、Genentech、AbbVie、Gilead Sciences、AstraZenecaなど2022年に、世界の上位5社は収益ベースで約 %のシェアを持っていた。 レポートには、以下の内容が含まれます。 本レポートでは、リンパ増殖性障害治療薬の世界市場規模を概観します。2018年~2022年の過去の市場収益データ、2023年の予測、2029年までのCAGRの予測など、世界市場の動向を分析します。 本レポートでは、リンパ増殖性障害治療薬の主要生産者を調査し、主要地域と国の収益も提供します。リンパ増殖性疾患治療薬の今後の市場可能性のハイライトと、この市場を様々なセグメントとサブセグメントに分けて予測するための主要地域/国の注目点。米国、カナダ、メキシコ、ブラジル、中国、日本、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他諸国の国別データおよび市場価値分析。 本レポートでは、2018年から2023年のデータをもとに、リンパ増殖性障害治療薬の収益、市場シェア、主要企業の業界ランキングに焦点を当てます。世界のリンパ増殖性障害治療市場の主要なステークホルダーを特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別の収益に基づき分析します。本レポートは、関係者が競争環境を理解し、より多くの洞察を得て、より良い方法で事業と市場戦略を位置づけるのに役立ちます。 本レポートでは、2018年から2029年までの、タイプ別、用途別のセグメントデータ、収益、成長率を分析しています。リンパ増殖性障害治療薬の収益、予測される成長動向、生産技術、用途、エンドユーザー産業の市場規模を評価・予測します。 Atara Biotherapeutics、Novartis、Janssen Global Services、MSD、Bristol-Myers Squibb、Genentech、AbbVie、Gilead Sciences、AstraZenecaなど、世界の主要企業の詳細な会社プロファイル。 会社別 アタラ・バイオセラピューティクス ノバルティス ヤンセン・グローバル・サービス さいだいゆうこうすうじ ブリストル・マイヤーズ スクイブ ジェネンテック アッヴィー ギリアド・サイエンシズ アストラゼネカ ファイザー タイプ別セグメント 免疫調節薬 ステロイド 細胞傷害剤 その他 アプリケーション別セグメント 白血病 リンパ腫 その他 地域別 北アメリカ ユーエスエー カナダ ヨーロッパ ドイツ フランス 連邦王国 イタリア ロシア 北欧諸国 その他のヨーロッパ アジア太平洋 中国 日本 南朝鮮 東南アジア インド オーストラリア その他のアジア ラテンアメリカ メキシコ ブラジル ラテンアメリカの残りの地域 中近東・アフリカ・中南米 トルコ サウジアラビア UAE MEAの残りの地域 章立て 第1章:報告書のスコープ、異なる市場セグメント(製品タイプ、アプリケーションなど)のエグゼクティブサマリー、各市場セグメントの市場規模、将来の発展可能性などを紹介します。市場の現状と、短中期および長期的にどのような進化を遂げる可能性があるのかについて、ハイレベルな視点で解説しています。 第2章 リンパ増殖性障害治療薬の世界および地域レベルでの収益。各地域とその主要国の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、今後の発展見通し、市場スペース、生産能力などを紹介しています。また、市場力学、市場の最新動向、市場の推進要因と制限要因、業界各社が直面する課題とリスク、業界の関連政策の分析などを紹介します。 第3章:リンパ増殖性障害治療薬企業の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、M&A情報などを詳細に分析。 第4章:各種市場セグメントをタイプ別に分析し、各市場セグメントの収益、発展可能性を網羅し、読者が異なる市場セグメントにおけるブルーオーシャン市場を見つけるのに役立ちます。 第5章:アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの収益、開発可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。 第6章:北米:タイプ別、アプリケーション別、国別、各セグメント別の収益。 第7章:ヨーロッパ:タイプ別、アプリケーション別、国別、各セグメントごとの収益。 第8章:中国 タイプ別、アプリケーション別、セグメント別の収益。 第9章:アジア(中国を除く) タイプ別、アプリケーション別、地域別、各セグメントごとの収益。 第10章 中東、アフリカ、中南米 タイプ別、アプリケーション別、国別、各セグメントごとの収益。 第11章:主要企業のプロファイルを提供し、製品の説明や仕様、リンパ増殖性障害治療薬の収益、粗利益率、最近の開発など、市場の主要企業の基本状況を詳細に紹介する。 第12章 アナリストの視点/結論 目次1 Report Overview1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Lymphoproliferative Disorder Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 1.2.2 Immunomodulatory Agents 1.2.3 Steroids 1.2.4 Cytotoxic Agents 1.2.5 Others 1.3 Market by Application 1.3.1 Global Lymphoproliferative Disorder Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 1.3.2 Leukaemia 1.3.3 Lymphomas 1.3.4 Others 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Lymphoproliferative Disorder Treatment Market Perspective (2018-2029) 2.2 Global Lymphoproliferative Disorder Treatment Growth Trends by Region 2.2.1 Lymphoproliferative Disorder Treatment Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Lymphoproliferative Disorder Treatment Historic Market Size by Region (2018-2023) 2.2.3 Lymphoproliferative Disorder Treatment Forecasted Market Size by Region (2024-2029) 2.3 Lymphoproliferative Disorder Treatment Market Dynamics 2.3.1 Lymphoproliferative Disorder Treatment Industry Trends 2.3.2 Lymphoproliferative Disorder Treatment Market Drivers 2.3.3 Lymphoproliferative Disorder Treatment Market Challenges 2.3.4 Lymphoproliferative Disorder Treatment Market Restraints 3 Competition Landscape by Key Players 3.1 Global Revenue Lymphoproliferative Disorder Treatment by Players 3.1.1 Global Lymphoproliferative Disorder Treatment Revenue by Players (2018-2023) 3.1.2 Global Lymphoproliferative Disorder Treatment Revenue Market Share by Players (2018-2023) 3.2 Global Lymphoproliferative Disorder Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Global Key Players of Lymphoproliferative Disorder Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023 3.4 Global Lymphoproliferative Disorder Treatment Market Concentration Ratio 3.4.1 Global Lymphoproliferative Disorder Treatment Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Lymphoproliferative Disorder Treatment Revenue in 2022 3.5 Global Key Players of Lymphoproliferative Disorder Treatment Head office and Area Served 3.6 Global Key Players of Lymphoproliferative Disorder Treatment, Product and Application 3.7 Global Key Players of Lymphoproliferative Disorder Treatment, Date of Enter into This Industry 3.8 Mergers & Acquisitions, Expansion Plans 4 Lymphoproliferative Disorder Treatment Breakdown Data by Type 4.1 Global Lymphoproliferative Disorder Treatment Historic Market Size by Type (2018-2023) 4.2 Global Lymphoproliferative Disorder Treatment Forecasted Market Size by Type (2024-2029) 5 Lymphoproliferative Disorder Treatment Breakdown Data by Application 5.1 Global Lymphoproliferative Disorder Treatment Historic Market Size by Application (2018-2023) 5.2 Global Lymphoproliferative Disorder Treatment Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Lymphoproliferative Disorder Treatment Market Size (2018-2029) 6.2 North America Lymphoproliferative Disorder Treatment Market Size by Type 6.2.1 North America Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 6.2.2 North America Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 6.2.3 North America Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 6.3 North America Lymphoproliferative Disorder Treatment Market Size by Application 6.3.1 North America Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 6.3.2 North America Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 6.3.3 North America Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 6.4 North America Lymphoproliferative Disorder Treatment Market Size by Country 6.4.1 North America Lymphoproliferative Disorder Treatment Market Size by Country: 2018 VS 2022 VS 2029 6.4.2 North America Lymphoproliferative Disorder Treatment Market Size by Country (2018-2023) 6.4.3 North America Lymphoproliferative Disorder Treatment Market Size by Country (2024-2029) 6.4.4 United States 6.4.5 Canada 7 Europe 7.1 Europe Lymphoproliferative Disorder Treatment Market Size (2018-2029) 7.2 Europe Lymphoproliferative Disorder Treatment Market Size by Type 7.2.1 Europe Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 7.2.2 Europe Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 7.2.3 Europe Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 7.3 Europe Lymphoproliferative Disorder Treatment Market Size by Application 7.3.1 Europe Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 7.3.2 Europe Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 7.3.3 Europe Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 7.4 Europe Lymphoproliferative Disorder Treatment Market Size by Country 7.4.1 Europe Lymphoproliferative Disorder Treatment Market Size by Country: 2018 VS 2022 VS 2029 7.4.2 Europe Lymphoproliferative Disorder Treatment Market Size by Country (2018-2023) 7.4.3 Europe Lymphoproliferative Disorder Treatment Market Size by Country (2024-2029) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 China 8.1 China Lymphoproliferative Disorder Treatment Market Size (2018-2029) 8.2 China Lymphoproliferative Disorder Treatment Market Size by Type 8.2.1 China Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 8.2.2 China Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 8.2.3 China Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 8.3 China Lymphoproliferative Disorder Treatment Market Size by Application 8.3.1 China Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 8.3.2 China Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 8.3.3 China Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 9 Asia (excluding China) 9.1 Asia Lymphoproliferative Disorder Treatment Market Size (2018-2029) 9.2 Asia Lymphoproliferative Disorder Treatment Market Size by Type 9.2.1 Asia Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 9.2.2 Asia Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 9.2.3 Asia Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 9.3 Asia Lymphoproliferative Disorder Treatment Market Size by Application 9.3.1 Asia Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 9.3.2 Asia Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 9.3.3 Asia Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 9.4 Asia Lymphoproliferative Disorder Treatment Market Size by Region 9.4.1 Asia Lymphoproliferative Disorder Treatment Market Size by Region: 2018 VS 2022 VS 2029 9.4.2 Asia Lymphoproliferative Disorder Treatment Market Size by Region (2018-2023) 9.4.3 Asia Lymphoproliferative Disorder Treatment Market Size by Region (2024-2029) 9.4.4 Japan 9.4.5 South Korea 9.4.6 China Taiwan 9.4.7 Southeast Asia 9.4.8 India 9.4.9 Australia 10 Middle East, Africa, and Latin America 10.1 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size (2018-2029) 10.2 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Type 10.2.1 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 10.2.2 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 10.2.3 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 10.3 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Application 10.3.1 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 10.3.2 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 10.3.3 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 10.4 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Country 10.4.1 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Country: 2018 VS 2022 VS 2029 10.4.2 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Country (2018-2023) 10.4.3 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Country (2024-2029) 10.4.4 Brazil 10.4.5 Mexico 10.4.6 Turkey 10.4.7 Saudi Arabia 10.4.8 Israel 10.4.9 GCC Countries 11 Key Players Profiles 11.1 Atara Biotherapeutics 11.1.1 Atara Biotherapeutics Company Details 11.1.2 Atara Biotherapeutics Business Overview 11.1.3 Atara Biotherapeutics Lymphoproliferative Disorder Treatment Introduction 11.1.4 Atara Biotherapeutics Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.1.5 Atara Biotherapeutics Recent Developments 11.2 Novartis 11.2.1 Novartis Company Details 11.2.2 Novartis Business Overview 11.2.3 Novartis Lymphoproliferative Disorder Treatment Introduction 11.2.4 Novartis Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.2.5 Novartis Recent Developments 11.3 Janssen Global Services 11.3.1 Janssen Global Services Company Details 11.3.2 Janssen Global Services Business Overview 11.3.3 Janssen Global Services Lymphoproliferative Disorder Treatment Introduction 11.3.4 Janssen Global Services Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.3.5 Janssen Global Services Recent Developments 11.4 MSD 11.4.1 MSD Company Details 11.4.2 MSD Business Overview 11.4.3 MSD Lymphoproliferative Disorder Treatment Introduction 11.4.4 MSD Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.4.5 MSD Recent Developments 11.5 Bristol-Myers Squibb 11.5.1 Bristol-Myers Squibb Company Details 11.5.2 Bristol-Myers Squibb Business Overview 11.5.3 Bristol-Myers Squibb Lymphoproliferative Disorder Treatment Introduction 11.5.4 Bristol-Myers Squibb Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.5.5 Bristol-Myers Squibb Recent Developments 11.6 Genentech 11.6.1 Genentech Company Details 11.6.2 Genentech Business Overview 11.6.3 Genentech Lymphoproliferative Disorder Treatment Introduction 11.6.4 Genentech Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.6.5 Genentech Recent Developments 11.7 AbbVie 11.7.1 AbbVie Company Details 11.7.2 AbbVie Business Overview 11.7.3 AbbVie Lymphoproliferative Disorder Treatment Introduction 11.7.4 AbbVie Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.7.5 AbbVie Recent Developments 11.8 Gilead Sciences 11.8.1 Gilead Sciences Company Details 11.8.2 Gilead Sciences Business Overview 11.8.3 Gilead Sciences Lymphoproliferative Disorder Treatment Introduction 11.8.4 Gilead Sciences Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.8.5 Gilead Sciences Recent Developments 11.9 AstraZeneca 11.9.1 AstraZeneca Company Details 11.9.2 AstraZeneca Business Overview 11.9.3 AstraZeneca Lymphoproliferative Disorder Treatment Introduction 11.9.4 AstraZeneca Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.9.5 AstraZeneca Recent Developments 11.10 Pfizer 11.10.1 Pfizer Company Details 11.10.2 Pfizer Business Overview 11.10.3 Pfizer Lymphoproliferative Disorder Treatment Introduction 11.10.4 Pfizer Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.10.5 Pfizer Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
SummaryLymphoproliferative disorder (LPD) are a group ofdiseases featured by uncontrolled and/or abnormal production of lymphocytes. Lymphocytes can be classified into T and B cells that regenerate abnormally to produce immunoproliferative disorders.LPD may furtherlead tohigh number of identical B cells that are found in the body. These problems often occur in individuals with low to very low immunity.T-cell lymphoproliferative disorders can be cured by allogeneic hematopoietic stem cell transplantation (HSCT).It may be also managed with the use of steroids, cyclosporine. A, and etoposide. Table of Contents1 Report Overview1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Lymphoproliferative Disorder Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 1.2.2 Immunomodulatory Agents 1.2.3 Steroids 1.2.4 Cytotoxic Agents 1.2.5 Others 1.3 Market by Application 1.3.1 Global Lymphoproliferative Disorder Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 1.3.2 Leukaemia 1.3.3 Lymphomas 1.3.4 Others 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Global Growth Trends 2.1 Global Lymphoproliferative Disorder Treatment Market Perspective (2018-2029) 2.2 Global Lymphoproliferative Disorder Treatment Growth Trends by Region 2.2.1 Lymphoproliferative Disorder Treatment Market Size by Region: 2018 VS 2022 VS 2029 2.2.2 Lymphoproliferative Disorder Treatment Historic Market Size by Region (2018-2023) 2.2.3 Lymphoproliferative Disorder Treatment Forecasted Market Size by Region (2024-2029) 2.3 Lymphoproliferative Disorder Treatment Market Dynamics 2.3.1 Lymphoproliferative Disorder Treatment Industry Trends 2.3.2 Lymphoproliferative Disorder Treatment Market Drivers 2.3.3 Lymphoproliferative Disorder Treatment Market Challenges 2.3.4 Lymphoproliferative Disorder Treatment Market Restraints 3 Competition Landscape by Key Players 3.1 Global Revenue Lymphoproliferative Disorder Treatment by Players 3.1.1 Global Lymphoproliferative Disorder Treatment Revenue by Players (2018-2023) 3.1.2 Global Lymphoproliferative Disorder Treatment Revenue Market Share by Players (2018-2023) 3.2 Global Lymphoproliferative Disorder Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Global Key Players of Lymphoproliferative Disorder Treatment, Ranking by Revenue, 2021 VS 2022 VS 2023 3.4 Global Lymphoproliferative Disorder Treatment Market Concentration Ratio 3.4.1 Global Lymphoproliferative Disorder Treatment Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Lymphoproliferative Disorder Treatment Revenue in 2022 3.5 Global Key Players of Lymphoproliferative Disorder Treatment Head office and Area Served 3.6 Global Key Players of Lymphoproliferative Disorder Treatment, Product and Application 3.7 Global Key Players of Lymphoproliferative Disorder Treatment, Date of Enter into This Industry 3.8 Mergers & Acquisitions, Expansion Plans 4 Lymphoproliferative Disorder Treatment Breakdown Data by Type 4.1 Global Lymphoproliferative Disorder Treatment Historic Market Size by Type (2018-2023) 4.2 Global Lymphoproliferative Disorder Treatment Forecasted Market Size by Type (2024-2029) 5 Lymphoproliferative Disorder Treatment Breakdown Data by Application 5.1 Global Lymphoproliferative Disorder Treatment Historic Market Size by Application (2018-2023) 5.2 Global Lymphoproliferative Disorder Treatment Forecasted Market Size by Application (2024-2029) 6 North America 6.1 North America Lymphoproliferative Disorder Treatment Market Size (2018-2029) 6.2 North America Lymphoproliferative Disorder Treatment Market Size by Type 6.2.1 North America Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 6.2.2 North America Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 6.2.3 North America Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 6.3 North America Lymphoproliferative Disorder Treatment Market Size by Application 6.3.1 North America Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 6.3.2 North America Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 6.3.3 North America Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 6.4 North America Lymphoproliferative Disorder Treatment Market Size by Country 6.4.1 North America Lymphoproliferative Disorder Treatment Market Size by Country: 2018 VS 2022 VS 2029 6.4.2 North America Lymphoproliferative Disorder Treatment Market Size by Country (2018-2023) 6.4.3 North America Lymphoproliferative Disorder Treatment Market Size by Country (2024-2029) 6.4.4 United States 6.4.5 Canada 7 Europe 7.1 Europe Lymphoproliferative Disorder Treatment Market Size (2018-2029) 7.2 Europe Lymphoproliferative Disorder Treatment Market Size by Type 7.2.1 Europe Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 7.2.2 Europe Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 7.2.3 Europe Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 7.3 Europe Lymphoproliferative Disorder Treatment Market Size by Application 7.3.1 Europe Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 7.3.2 Europe Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 7.3.3 Europe Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 7.4 Europe Lymphoproliferative Disorder Treatment Market Size by Country 7.4.1 Europe Lymphoproliferative Disorder Treatment Market Size by Country: 2018 VS 2022 VS 2029 7.4.2 Europe Lymphoproliferative Disorder Treatment Market Size by Country (2018-2023) 7.4.3 Europe Lymphoproliferative Disorder Treatment Market Size by Country (2024-2029) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 China 8.1 China Lymphoproliferative Disorder Treatment Market Size (2018-2029) 8.2 China Lymphoproliferative Disorder Treatment Market Size by Type 8.2.1 China Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 8.2.2 China Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 8.2.3 China Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 8.3 China Lymphoproliferative Disorder Treatment Market Size by Application 8.3.1 China Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 8.3.2 China Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 8.3.3 China Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 9 Asia (excluding China) 9.1 Asia Lymphoproliferative Disorder Treatment Market Size (2018-2029) 9.2 Asia Lymphoproliferative Disorder Treatment Market Size by Type 9.2.1 Asia Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 9.2.2 Asia Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 9.2.3 Asia Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 9.3 Asia Lymphoproliferative Disorder Treatment Market Size by Application 9.3.1 Asia Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 9.3.2 Asia Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 9.3.3 Asia Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 9.4 Asia Lymphoproliferative Disorder Treatment Market Size by Region 9.4.1 Asia Lymphoproliferative Disorder Treatment Market Size by Region: 2018 VS 2022 VS 2029 9.4.2 Asia Lymphoproliferative Disorder Treatment Market Size by Region (2018-2023) 9.4.3 Asia Lymphoproliferative Disorder Treatment Market Size by Region (2024-2029) 9.4.4 Japan 9.4.5 South Korea 9.4.6 China Taiwan 9.4.7 Southeast Asia 9.4.8 India 9.4.9 Australia 10 Middle East, Africa, and Latin America 10.1 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size (2018-2029) 10.2 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Type 10.2.1 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Type (2018-2023) 10.2.2 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Type (2024-2029) 10.2.3 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Share by Type (2018-2029) 10.3 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Application 10.3.1 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Application (2018-2023) 10.3.2 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Application (2024-2029) 10.3.3 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Share by Application (2018-2029) 10.4 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Country 10.4.1 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Country: 2018 VS 2022 VS 2029 10.4.2 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Country (2018-2023) 10.4.3 Middle East, Africa, and Latin America Lymphoproliferative Disorder Treatment Market Size by Country (2024-2029) 10.4.4 Brazil 10.4.5 Mexico 10.4.6 Turkey 10.4.7 Saudi Arabia 10.4.8 Israel 10.4.9 GCC Countries 11 Key Players Profiles 11.1 Atara Biotherapeutics 11.1.1 Atara Biotherapeutics Company Details 11.1.2 Atara Biotherapeutics Business Overview 11.1.3 Atara Biotherapeutics Lymphoproliferative Disorder Treatment Introduction 11.1.4 Atara Biotherapeutics Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.1.5 Atara Biotherapeutics Recent Developments 11.2 Novartis 11.2.1 Novartis Company Details 11.2.2 Novartis Business Overview 11.2.3 Novartis Lymphoproliferative Disorder Treatment Introduction 11.2.4 Novartis Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.2.5 Novartis Recent Developments 11.3 Janssen Global Services 11.3.1 Janssen Global Services Company Details 11.3.2 Janssen Global Services Business Overview 11.3.3 Janssen Global Services Lymphoproliferative Disorder Treatment Introduction 11.3.4 Janssen Global Services Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.3.5 Janssen Global Services Recent Developments 11.4 MSD 11.4.1 MSD Company Details 11.4.2 MSD Business Overview 11.4.3 MSD Lymphoproliferative Disorder Treatment Introduction 11.4.4 MSD Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.4.5 MSD Recent Developments 11.5 Bristol-Myers Squibb 11.5.1 Bristol-Myers Squibb Company Details 11.5.2 Bristol-Myers Squibb Business Overview 11.5.3 Bristol-Myers Squibb Lymphoproliferative Disorder Treatment Introduction 11.5.4 Bristol-Myers Squibb Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.5.5 Bristol-Myers Squibb Recent Developments 11.6 Genentech 11.6.1 Genentech Company Details 11.6.2 Genentech Business Overview 11.6.3 Genentech Lymphoproliferative Disorder Treatment Introduction 11.6.4 Genentech Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.6.5 Genentech Recent Developments 11.7 AbbVie 11.7.1 AbbVie Company Details 11.7.2 AbbVie Business Overview 11.7.3 AbbVie Lymphoproliferative Disorder Treatment Introduction 11.7.4 AbbVie Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.7.5 AbbVie Recent Developments 11.8 Gilead Sciences 11.8.1 Gilead Sciences Company Details 11.8.2 Gilead Sciences Business Overview 11.8.3 Gilead Sciences Lymphoproliferative Disorder Treatment Introduction 11.8.4 Gilead Sciences Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.8.5 Gilead Sciences Recent Developments 11.9 AstraZeneca 11.9.1 AstraZeneca Company Details 11.9.2 AstraZeneca Business Overview 11.9.3 AstraZeneca Lymphoproliferative Disorder Treatment Introduction 11.9.4 AstraZeneca Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.9.5 AstraZeneca Recent Developments 11.10 Pfizer 11.10.1 Pfizer Company Details 11.10.2 Pfizer Business Overview 11.10.3 Pfizer Lymphoproliferative Disorder Treatment Introduction 11.10.4 Pfizer Revenue in Lymphoproliferative Disorder Treatment Business (2018-2023) 11.10.5 Pfizer Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野の最新刊レポート
QYResearch 社の最新刊レポート本レポートと同じKEY WORD()の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/09/12 10:27 143.85 円 158.71 円 190.22 円 |